OTCMKTS:NVZMY - NOVOZYMES A/S/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $48.0850 +0.27 (+0.58 %) (As of 05/24/2019 04:00 PM ET)Previous Close$47.81Today's Range$47.70 - $48.1952-Week Range$40.38 - $55.84Volume8,057 shsAverage Volume29,148 shsMarket Capitalization$14.28 billionP/E Ratio27.48Dividend Yield1.05%Beta0.83 ProfileAnalyst RatingsChartDividendEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Receive NVZMY News and Ratings via Email Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorBasic Materials Current SymbolOTCMKTS:NVZMY Previous Symbol CUSIPN/A CIKN/A Webhttp://www.novozymes.com/ Phone45-4446-0000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E Ratio27.48 Forward P/E Ratio27.01 P/E Growth2.37 Sales & Book Value Annual Sales$2.28 billion Price / Sales6.26 Cash Flow$1.8813 per share Price / Cash Flow25.56 Book Value$6.81 per share Price / Book7.06Profitability EPS (Most Recent Fiscal Year)$1.75 Net Income$511.29 million Net Margins22.14% Return on Equity29.64% Return on Assets16.60%Miscellaneous Employees6,245 Outstanding Shares297,000,000Market Cap$14.28 billion Next Earnings Date5/29/2019 (Estimated) OptionableNot Optionable NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions What is NOVOZYMES A/S/S's stock symbol? NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY." How often does NOVOZYMES A/S/S pay dividends? What is the dividend yield for NOVOZYMES A/S/S? NOVOZYMES A/S/S declared an annual dividend on Thursday, February 7th. Stockholders of record on Friday, March 1st will be paid a dividend of $0.504 per share on Tuesday, March 19th. This represents a dividend yield of 1.16%. The ex-dividend date is Thursday, February 28th. View NOVOZYMES A/S/S's Dividend History. When is NOVOZYMES A/S/S's next earnings date? NOVOZYMES A/S/S is scheduled to release their next quarterly earnings announcement on Wednesday, May 29th 2019. View Earnings Estimates for NOVOZYMES A/S/S. What is the consensus analysts' recommendation for NOVOZYMES A/S/S? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NOVOZYMES A/S/S. Has NOVOZYMES A/S/S been receiving favorable news coverage? Press coverage about NVZMY stock has trended positive recently, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NOVOZYMES A/S/S earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of NOVOZYMES A/S/S's key competitors? Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA). What other stocks do shareholders of NOVOZYMES A/S/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other NOVOZYMES A/S/S investors own include ManpowerGroup (MAN), TeamHealth (TMH), Novo Nordisk A/S (NVO), DANSKE BK A/S/S (DNKEY), FOX (FOXA), Level One Bancorp (LEVL), Anadarko Petroleum (APC), Duke Energy (DUK), Emerson Electric (EMR) and Zayo Group (ZAYO). Who are NOVOZYMES A/S/S's key executives? NOVOZYMES A/S/S's management team includes the folowing people: Mr. Peder Holk Nielsen, Pres & CEO (Age 63)Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 44)Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 59)Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 56)Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 46) How do I buy shares of NOVOZYMES A/S/S? Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NOVOZYMES A/S/S's stock price today? One share of NVZMY stock can currently be purchased for approximately $48.0850. How big of a company is NOVOZYMES A/S/S? NOVOZYMES A/S/S has a market capitalization of $14.28 billion and generates $2.28 billion in revenue each year. The biotechnology company earns $511.29 million in net income (profit) each year or $1.75 on an earnings per share basis. NOVOZYMES A/S/S employs 6,245 workers across the globe. What is NOVOZYMES A/S/S's official website? The official website for NOVOZYMES A/S/S is http://www.novozymes.com/. How can I contact NOVOZYMES A/S/S? NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected] MarketBeat Community Rating for NOVOZYMES A/S/S (OTCMKTS NVZMY)Community Ranking: 1.7 out of 5 ()Outperform Votes: 81 (Vote Outperform)Underperform Votes: 164 (Vote Underperform)Total Votes: 245MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote "Outperform" if you believe NVZMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Total Return Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.